The significant rise in new GLP-1 RA prescriptions between 2011 and 2023 saw a doubling in the proportion written for obesity and a decline in those for T2D.
Adiposity before age 60 to 64 years, beginning as early as age 20 years, was associated with adverse cardiac structure and function not explained by current BMI.
The oral GLP-1 RA was associated with weight loss of 7.3% in just 4 weeks and is designed with unique properties that will enhance multiple outcomes, Roche said.